Theravance Biopharma, Inc. (TBPH)
17.60
-0.20
(-1.15%)
USD |
NASDAQ |
Dec 10, 16:00
17.60
0.00 (0.00%)
After-Hours: 20:00
Theravance Biopharma Cash from Investing (Quarterly): -100.25M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Perspective Therapeutics, Inc. | 13.99M |
| Skye Bioscience, Inc. | 7.967M |
| FibroGen, Inc. | 87.16M |
| Myomo, Inc. | 0.1897M |
| VYNE Therapeutics, Inc. | 4.402M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -6.508M |
| Cash from Financing (Quarterly) | -0.40M |
| Free Cash Flow | 243.48M |
| Free Cash Flow Per Share (Quarterly) | -0.1254 |
| Free Cash Flow to Equity (Quarterly) | -4.646M |
| Free Cash Flow to Firm (Quarterly) | -7.225M |
| Free Cash Flow Yield | 27.43% |